🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This Thursday at #BIO2023, Lightstone Partner Christina Isacson, will discuss the role of health systems within the commercialization of new therapies alongside fellow industry experts. Panel details here: bit.ly/3Nd0Acz

Lightstone portfolio company, Intracept by Boston Scientific, recently announced the publication of three-year pooled results from the #Intracept Procedure, demonstrating long-term pain relief and reduced opioid use for patients with vertebrogenic pain. Learn more: bit.ly/3PaZi3g

Congrats to Tagworks Pharmaceuticals, on the closing of their Series A financing! Lightstone is a proud fund partner, and we look forward to updates as the company advances their lead ADC program, TGW101, and their proprietary Click-to-Release platform. Learn more: tagworkspharma.com/tagworks-pharm…

Congrats to FIRE1 on successfully implanting the first U.S. patients with its FIRE1™ System for remote heart failure monitoring in a study that will assess the Company’s technology to improve outcomes for heart failure patients. Learn more: bwnews.pr/3Dl7ab7

Congrats to @Cerevance for being named one of FierceBiotech’s 2023 #Fierce15 biotech companies. We’re looking forward to seeing more great accomplishments from Cerevance in the future!

Congratulations to Nimbus Therapeutics, on the closing of their $210 million private financing! Lightstone is a proud fund partner, and we look forward to updates as the company advances their pipeline in immunology, cancer and metabolic disease. Learn more: bit.ly/3LfQSF4

Congrats Intracept by Boston Scientific, whose agreement to be acquired by Boston Scientific was announced. The company’s therapy, the Intracept® Procedure, is their FDA-cleared treatment for chronic #vertebrogenic pain. Great news and great for patients! Learn more here: bit.ly/3EP7fEE

Sharing an exciting update from Cerevance, who recently announced that the first patient has been dosed in their Phase 1 study evaluating safety and tolerability of CVN293, for the treatment of #ALS and #Alzheimers. Full press release: bit.ly/3Lyr4nL

Today, ALX Oncology shared encouraging positive interim Phase 2 data from their ASPEN-06 clinical trial evaluating evorpacept, for the treatment of advanced HER2-positive gastric cancer. Full press release here: bit.ly/45fZ8fe

Today, the launch of 65LAB was announced, a company creation vehicle designed to advance drug discovery & new therapeutics companies in Singapore. As a proud founding partner, we look forward to the potential patient impact of these discoveries. Read more: prn.to/3LJD0TO

Exciting news from Cerevance, who dosed the first patient in their ASCEND Phase 2 clinical study of CVN424 for the treatment of individuals with Parkinson’s Disease. We look forward to future updates! Full press release: bit.ly/49CufF4

Congratulations to Intracept by Boston Scientific, that has developed and commercialized the Intracept® Procedure, their FDA-cleared treatment for chronic #vertebrogenic pain, on being acquired by Boston Scientific! Great news and great for patients. Learn more here: bit.ly/3sNpJTH

Congratulations to Jingjing Wang, Ph.D. on her promotion to Vice President at Lightstone! As a core member of our investment team, we look forward to exciting things to come as we continue our work together.

Welcome José-Alain Sahel, M.D., to Lightstone, joining us as an advisor. A distinguished professor and leader in the Ophthalmology and Neuroscience space, Dr. Sahel’s deep knowledge will play a key role in supporting new and existing portfolio companies.

Congrats to Cerevance, who announced the closing of their Series B-1 Extension financing round. Lightstone is a proud fund partner, and we look forward to company updates as they progress their pipeline of therapies for CNS diseases. Read more: bit.ly/44jBxeS

Lightstone portfolio company VoltaMedical announced positive results from their TAILORED-AF trial, comparing AI-assisted ablation procedure with the conventional treatment for persistent atrial fibrillation patients. Learn more about what was presented: bit.ly/3yEkKXW

We welcome Ken Mills as CEO and member of the Board of Directors for @tagworkspharma as the company expects to embark on its next phase of growth and enter the clinic in 2025 with its lead antibody-drug conjugate program, TGW101.

Congratulations to Brendan Kelly, PhD, on his promotion to Principal at Lightstone Ventures! As a core member of our investment team, we celebrate Brendan’s leadership and contributions across our portfolio. We look forward to continuing our exciting work together!

Please join us in welcoming H. Martin Seidel, Ph.D., to the Lightstone team as Advisor. Dr. Seidel brings over 30 years of experience across R&D and Business Development in both pharma and biotech to our team. We look forward to working with you!

Congrats to Tagworks Pharmaceuticals on this significant milestone! Great news for patients as the Company enters clinical development of their Phase 1 trial of TGW101, a first-in-class antibody drug-conjugate targeting tumor associated glycoprotein 72 (TAG-72) in advanced #solidtumors.